Paraoksonaz ve Kanser

Abstract

Paraoksonaz (PON) enzimi, kalsiyum baðýmlý bir aromatik hidrolazdýr. LDL ve HDL’nin oksidasyondan korunmasýnda, hücre membranlarýnda lipit peroksidasyonuna karºý antioksidan etkide ve antiinflamatuar süreçte önemli rol oynadýðýna inanýlmaktadýr. Reaktif oksijen türleri, reaktivitesi yüksektir ve hemen hemen tüm hücre komponentlerine saldýrarak dokularda hasara yol açabilirler. Oksidatif stresin ve serbest oksijen radikallerinin artmasý, çeºitli kanser türlerinin riskinin artmasýyla iliºkilidir. Lipid peroksidasyonu son ürünleri ve serbest oksijen radikallerinin, onkogenez için baºlatýcý role sahip olduðu düºünülmektedir. Bazý araºtýrmalarda PON mutasyonu ile kanser riski arasýnda pozitif korelasyonlar saptanmýºtýr. Gelecekteki çalýºmalarda serum PON aktivitesinin kanser riski içi prediktif risk faktörü olarak deðerlendirilebileceði belirtilmektedir

Keywords

• Paraoksonaz, Arilesteraz, Kanser

References

1. 1. Juretic D, Tadijanovic M, Rekic B, Simean-Rudolf V, Reiner E, Baricic M. Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. Clin Sci 2001; 42: 146-150.
2. 2. Li WF, Costa LG, Furlong CE. Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol and Environ Health 1993; 40: 337-346.
3. 3. ÷zt¸rk H. Diabetes Mellitusída Paraoksonaz Aktivitesi ve AOPP D¸zeyleri. T˝bbi Biyokimya Uzmanl˝k Tezi, Tez Yˆneticisi: Eren E, ›stanbul, 2008
4. 4. Primo-Parma SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of multigene family. Genomics 1996; 33: 498-509. 5. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69-76.
5. 6. Canales A, Sanchez-Muniz FJ. Paraoxonase, something more than an enzyme? Med Clin (Barc) 2003;121:537ñ48.
6. 7. Mackness B, Mackness MI, Arrol S, Turkei W, Durrington PN. The effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Letters 1998; 423: 57-60.
7. 8. Ferretti G, Bacchetti T, Busni D, Rabini RA, Curatola G. Protective effect of paraoxonase activity in high- density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type1 diabetic patients. J Clin Endocrinol Metab 2004; 89: 2957-62.
8. 9. Ferretti G, Bacchetti T, Moroni C ve ark. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab 2005;90: 1728-33.

9. 10. Draganov DI, Teiber JF, Speelman A, Osawa Y,Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005; 46: 1239-1247
10. 11. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52: 598-608.
11. 12. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stres-induced cancer. Chem Biol Interact 2006; 160:1-40.
12. 13. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/ arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-1138.
13. 14. Mackness MI, Arroll SI, Mackness B, Durrington PN. Alloenzymes of paraoxonase and effectiveness of high density lipoproteins in protecting low density lipoprotein against lipid peroxidation. Lancet 1997; 349: 851-852.
14. 15. Geldmacher-von Mallinckrodt M, Diepgen TL, Duhme C, Hommel G. A study of the polymorphism and ethnic distribution differences of human serum paraoxonase. Am J Phys Anthropol 1983;62: 235-241.
15. 16. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998, 31:329-336.
16. 17. Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atheroscler Suppl 2002, 3:49-55.
17. 18. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999, 19:330-335.
18. 19. Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86:193-199.
19. 20. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998; 31:329-336.
20. 21. Weber WW. Influence of heredity on human sensitivity to environmental chemicals. Environ Mol Mutagen 1995,25(Suppl26):102-114.
21. 22. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stres induced cancer. Chem Biol Interact 2006; 160:1-40.
22. 23. Dreher D, Junod AF. Role of oxygen free radicals in cancer development. Eur J Cancer 1996; 32A:30-38.
23. 24. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 2003; 34:774-784.
24. 25. Kaynar H, Meral M, Turhan H, Keles M, Celik G, Akcay F. Glutathione peroxidase, glutathione-Stransferase, catalase, xanthine oxidase, Cu-Zn superoxide dismutase activities, total glutathione, nitric oxide, and malondialdehyde levels in erythrocytes of patients with small cell and non-small cell lung cancer. Cancer Lett 2005; 227:133-139.
25. 26. Gonenc A, Ozkan Y, Torun M, Simsek B. Plasma malondialdehyde (MDA) levels in breast and lung cancer patients. J ClinPharm Ther 2001; 26:141-144.
26. 27. Lee CH, Lee KY, Choe KH, et al. Effects of oxidative DNA damage induced by polycyclic aromatic hydrocarbons and genetic polymorphism of the paraoxonase-1 (PON1) gene on lung cancer. J Prev Med Pub Health 2005; 38:345-350.
27. 28. Elkiran TE, Mar N, Aygen B, Gursu F, Karaoglu A, Koca S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 2007;7:48.
28. 29. James RW, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 2000; 101:2252-2257.
29. 30. Antognelli C, Mearini L, Talesa VN, Giannantoni A, Mearini E. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 2005; 63:240-251.
30. 31. Marchesani M, Hakkarainen A, Tuomainen TP, et al. New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men. J Natl Cancer Inst 2003; 95:812 818.
31. 32. Antognelli C, Del Buono C, Ludovini V, et al. CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case control study. BMC Cancer 2009;9:115.
32. 33. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998; 31(3):329- 336.
33. 34. FerrË N, Camps J, Fernandez-Ballart J, et al. Regulation of Serum Paraoxonase Activity by Genetic, Nutritional, and Lifestyle Factors in the General Population. Clin Chem 2003; 49(9):1491-1497.
34. 35. Akcay MN, Polat MF, Yilmaz I, Akcay G. Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 2003; 50(Suppl 2):ccxxv-ccxxvii.
35. 36. Akcay MN, Yilmaz I, Polat MF, Akcay G. Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 2003; 50(Suppl 2):cclxxiii-cclxxv.